We recently shared the news with you that the Genentech/Roche clinical trial of the huntingtin-lowering drug RG6042 is coming to NZ. For information on the NZ arm of the trial head over to our news section. Here we explain the science behind the drug RG6042.
In the last decade, a group of researchers from the University of Auckland’s Centre for Brain Research developed a sheep model for Huntington’s disease. They did this in the hope that it would help to reveal what happens to the brain in the pre-symptomatic stages of the disease.
New Zealand researcher Dr Ailsa McGregor is working to find treatments for Huntington’s disease. Ailsa and her team are currently testing a drug that may be able to ease the symptoms of Huntington’s disease in the early stages.
Researchers know that when the medium spiny neurons start to die, the globus pallidus as a whole begins to shrink, but they hadn’t figured out why it was shrinking. In this research, scientists were able to examine each part of the globus pallidus and determine which parts were being affected and how they were being affected.